title: Impact of HCV genetic differences on pathobiology of disease.
abstract: Multiple HCV genotypes have been isolated worldwide. Genotype seems to be involved in the main pathological aspects of HCV infection. Insulin resistance, steatosis and progression toward cirrhosis, fibrosis and hepatocellular carcinoma establish and develop following genotype-specific mechanisms. Moreover genotype influences pharmacological treatment in term of dose and duration. Pathways involved in cell proliferation, apoptosis, lipid metabolism, insulin and interferon signaling are impaired to a different extent among genotypes, leading to distinct pathological settings. Genotype 1 is associated with a more aggressive disease with increased insulin resistance, worst response to therapy, higher risk of cirrhosis and hepatocellular carcinoma development, while genotype 3 is associated with increased steatosis and fibrosis. The identification and characterization of HCV types and subtypes provides insight into the different outcome of HCV infection and responsiveness to therapy. In the present article, we focused on the pathogenicity of HCV genotypes and their effect on disease progression and treatment.
authors: Gastroenterology Unit IRCCS Casa Sollievo della Sofferenza Hospital, viale dei Cappuccini n.1, 71013 San Giovanni Rotondo, Italy.
authors: Maria
authors: M
authors: Ripoli
authors: Valerio
authors: V
authors: Pazienza
mesh_terms: D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology / Q000821:virology*; D018450:Disease Progression; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D005234:Fatty Liver / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology / Q000821:virology*; D056726:Genetic Association Studies; D005838:Genotype; D016174:Hepacivirus / Q000145:classification / Q000235:genetics* / Q000378:metabolism; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology / Q000821:virology*; D054884:Host-Pathogen Interactions; D006801:Humans; D007333:Insulin Resistance; D050356:Lipid Metabolism; D008103:Liver Cirrhosis / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology / Q000821:virology*; D008113:Liver Neoplasms / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology / Q000821:virology*; D058889:Molecular Typing; D012720:Severity of Illness Index
chemical_list: D000998:Antiviral Agents; D004791:Enzyme Inhibitors